Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Thursday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.47) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Acumen Pharmaceuticals Trading Down 4.0 %

NASDAQ ABOS opened at $1.19 on Wednesday. Acumen Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $4.28. The company has a fifty day simple moving average of $1.40 and a two-hundred day simple moving average of $2.01. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The stock has a market cap of $71.50 million, a P/E ratio of -0.86 and a beta of 0.02.

Insider Buying and Selling at Acumen Pharmaceuticals

In related news, CFO Matt Zuga sold 28,902 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total value of $49,711.44. Following the completion of the transaction, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52. Following the sale, the chief executive officer now owns 454,707 shares in the company, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 131,526 shares of company stock valued at $233,124. 7.10% of the stock is owned by insiders.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.